Loree M Larratt

Author PubWeight™ 10.17^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.	Blood	2002	2.38
2	Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.	Blood	2005	1.81
3	Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.	J Clin Oncol	2007	1.76
4	5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.	J Clin Oncol	2009	1.24
5	Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.	Leuk Res	2009	0.82
6	CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.	Transfusion	2008	0.82
7	Caterpillar-induced bleeding syndrome in a returning traveller.	CMAJ	2008	0.78
8	Membrane Type-1 Matrix Metalloproteinase Expression in Acute Myeloid Leukemia and Its Upregulation by Tumor Necrosis Factor-α.	Cancers (Basel)	2012	0.76